XML 46 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
The Company and Summary of Significant Accounting Policies (Details) (USD $)
0 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended
Mar. 04, 2013
Dec. 31, 2014
Segment
Dec. 31, 2013
Feb. 18, 2015
Feb. 03, 2014
Jan. 31, 2013
Feb. 28, 2014
Company Basis of Presentation (Textual) [Abstract]              
Date of completion of business combination with Nuvelo   Jan. 27, 2009          
Revenues   $ 0us-gaap_Revenues          
Fund raised through sale of convertible preferred and common stock     19,300,000us-gaap_ProceedsFromIssuanceOrSaleOfEquity        
Proceeds from the issuance of common stock   9,038,000us-gaap_ProceedsFromIssuanceOfCommonStock 1,741,000us-gaap_ProceedsFromIssuanceOfCommonStock        
Notification for delisting of shares   On February 18, 2015, we received notification from NASDAQ of potential delisting of our shares from the NASDAQ Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days. NASDAQ rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period.          
Reverse stock split 1-for-6 reverse split            
Concentrations of credit risk   0us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure          
Number of segments   1us-gaap_NumberOfOperatingSegments          
Subsequent Event              
Company Basis of Presentation (Textual) [Abstract]              
Minimum closing bid price of common stock       $ 1.00abio_ClosingBidPriceOfCommonStock
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
     
Number of grace days provided by NASDAQ to meet continued listing standard       180 days      
Registered Direct Offering              
Company Basis of Presentation (Textual) [Abstract]              
Proceeds from the issuance of common stock         $ 8,700,000us-gaap_ProceedsFromIssuanceOfCommonStock
/ us-gaap_SubsidiarySaleOfStockAxis
= abio_RegisteredDirectOfferingMember
$ 730,000us-gaap_ProceedsFromIssuanceOfCommonStock
/ us-gaap_SubsidiarySaleOfStockAxis
= abio_RegisteredDirectOfferingMember
$ 7,900,000us-gaap_ProceedsFromIssuanceOfCommonStock
/ us-gaap_SubsidiarySaleOfStockAxis
= abio_RegisteredDirectOfferingMember
Phase 3 heart failure (HF) trial of Gencaro | BEST Trial              
Company Basis of Presentation (Textual) [Abstract]              
Number of patients   2,708abio_NumberOfPatients
/ abio_ClinicalTrialsByPhaseAxis
= abio_PhaseThreeHeartFailureMember
/ us-gaap_HealthCareTrustFundAxis
= abio_BestTrialMember
         
Phase 3 heart failure (HF) trial of Gencaro | GENETIC-AF Trial              
Company Basis of Presentation (Textual) [Abstract]              
Number of patients company plans to enroll   420abio_NumberOfPatientsCompanyPlansToEnroll
/ abio_ClinicalTrialsByPhaseAxis
= abio_PhaseThreeHeartFailureMember
/ us-gaap_HealthCareTrustFundAxis
= abio_GENETICAFTrialMember
         
Phase Two B Heart Failure | GENETIC-AF Trial              
Company Basis of Presentation (Textual) [Abstract]              
Number of patients company plans to enroll   200abio_NumberOfPatientsCompanyPlansToEnroll
/ abio_ClinicalTrialsByPhaseAxis
= abio_PhaseTwoBHeartFailureMember
/ us-gaap_HealthCareTrustFundAxis
= abio_GENETICAFTrialMember
         
Original              
Company Basis of Presentation (Textual) [Abstract]              
Business combination with Nuvelo, date of agreement   Sep. 24, 2008          
Amendment              
Company Basis of Presentation (Textual) [Abstract]              
Business combination with Nuvelo, date of agreement   Oct. 28, 2008